Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Fevipiprant (NVP-QAW039) is a selective, potent, reversible competitive CRTh2 antagonist.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 47.00 | |
10 mg | In stock | $ 72.00 | |
25 mg | In stock | $ 147.00 | |
50 mg | In stock | $ 228.00 | |
100 mg | In stock | $ 372.00 | |
200 mg | In stock | $ 549.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 52.00 |
Description | Fevipiprant (NVP-QAW039) is a selective, potent, reversible competitive CRTh2 antagonist. |
Targets&IC50 | CRTH2:0.44 nM |
In vitro | CRTh2-mediated shape change in eosinophils was used to profile QAW039 in whole blood and represents a physiologically relevant environment. The comparable IC50 values for QAW039 in the whole blood and isolated shape-change assays are consistent with its lower plasma-protein binding and its relatively slow dissociation kinetics that drive its increased potency .QAW039 is highly potent in whole-blood systems, with the IC50 value obtained consistent with the affinity values calculated from radioligand experiments. In a further disease-relevant cellular context, the potency of QAW039 in the isolated Th2 cell cytokine inhibition assay is consistent with its CRTh2 receptor affinity, and, as with eosinophil assay readouts, this represents an improved potency compared with QAV680.[ |
Synonyms | QAW039, NVP-QAW039 |
Molecular Weight | 426.41 |
Formula | C19H17F3N2O4S |
CAS No. | 872365-14-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 32 mg/mL
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Fevipiprant 872365-14-5 Endocrinology/Hormones GPCR/G Protein Immunology/Inflammation GPR Prostaglandin Receptor QAW039 IL-4 inhibit Inhibitor bronchial asthma QAW-039 NVP-QAW-039 Th2 cells abdominal aortic aneurysm NVP-QAW039 orally active QAW 039 NVP-QAW 039 inhibitor